Research Article

You have full text access to this OnlineOpen article

Differential recognition of heat-shock protein dnaJ–derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis

  1. Margherita Massa1,
  2. Maristella Passalia1,
  3. Silvia Magni Manzoni2,
  4. Rita Campanelli1,
  5. Laura Ciardelli2,
  6. Gisella Puga Yung3,
  7. Sylvia Kamphuis4,
  8. Angela Pistorio5,
  9. Valentina Meli6,
  10. Alessandro Sette7,
  11. Berent Prakken4,†,
  12. Alberto Martini8,
  13. Salvatore Albani9,†,*

Article first published online: 27 APR 2007

DOI: 10.1002/art.22567

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 56, Issue 5, pages 1648–1657, May 2007

Additional Information

How to Cite

Massa, M., Passalia, M., Manzoni, S. M., Campanelli, R., Ciardelli, L., Yung, G. P., Kamphuis, S., Pistorio, A., Meli, V., Sette, A., Prakken, B., Martini, A. and Albani, S. (2007), Differential recognition of heat-shock protein dnaJ–derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis. Arthritis & Rheumatism, 56: 1648–1657. doi: 10.1002/art.22567

Author Information

  1. 1

    Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, and EUREKA Institute for Translational Medicine, Siracusa, Italy

  2. 2

    Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

  3. 3

    University of California, San Diego, La Jolla, California, and EUREKA Institute for Translational Medicine, Siracusa, Italy

  4. 4

    University Medical Center Utrecht, Utrecht, The Netherlands, and EUREKA Institute for Translational Medicine, Siracusa, Italy

  5. 5

    IRCCS G. Gaslini, Genoa, Italy

  6. 6

    Androclus Therapeutics, Milan, Italy, and EUREKA Institute for Translational Medicine, Siracusa, Italy

  7. 7

    La Jolla Institute for Allergy and Immunology, La Jolla, California

  8. 8

    IRCCS G. Gaslini, University of Genoa, Genoa, Italy, and EUREKA Institute for Translational Medicine, Siracusa, Italy

  9. 9

    University of California, San Diego, La Jolla, California, Androclus Therapeutics, Milan, Italy, and EUREKA Institute for Translational Medicine, Siracusa, Italy

  1. †

    Drs. Prakken and Albani are coinventors of concepts and sequences, patents for which are owned by University of California, San Diego.

*University of California at San Diego, Departments of Medicine and Pediatrics, 9500 Gilman Drive, La Jolla, CA 92093-0731

Publication History

  1. Issue published online: 27 APR 2007
  2. Article first published online: 27 APR 2007
  3. Manuscript Accepted: 24 JAN 2007
  4. Manuscript Received: 20 DEC 2005

Funded by

  • “Ricerca Corrente” grants from the IRCCS Policlinico San Matteo, Pavia, Italy

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (217K)

REFERENCES

  • 1
    Albani S, Ravelli A, Massa M, De Benedetti F, Andree G, Roudier J, et al. Immune responses to the Escherichia coli dnaJ heat shock protein in juvenile rheumatoid arthritis and their correlation with disease activity. J Pediatr 1994; 124: 561–5.
  • 2
    Albani S, Keystone EC, Nelson JL, Ollier WE, La Cava A, Montemayor AC, et al. Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nat Med 1995; 5: 448–52.
  • 3
    Albani S. Infection and molecular mimicry in autoimmune diseases of childhood. Clin Exp Rheumatol 1994; 12 Suppl 10: S35–41.
  • 4
    Prakken BJ, van der Zee R, Anderton SM, van Kooten P, Kuis W, van Eden W. Tolerance to an arthritogenic T-cell epitope of HSP65 and the regulation of experimental arthritis. Ann N Y Acad Sci 1996; 778: 425–6.
    Direct Link:
  • 5
    Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with heat-shock protein peptide (DiaPep277): a randomized, double-blind, phase II trial. Lancet 2002; 358: 1749–53.
  • 6
    Anderton SM, Wraith DC. Selection and fine-tuning of the autoimmune T-cell repertoire. Nat Rev Immunol 2002; 2: 487–98.
  • 7
    De Kleer IM, Kamphuis SM, Rijkers GT, Scholtens L, Gordon G, de Jager W, et al. The spontaneous remission of juvenile idiopathic arthritis is characterized by CD30+ T cells directed to human heat-shock protein 60 capable of producing the regulatory cytokine interleukin-10. Arthritis Rheum 2003; 48: 2001–10.
    Direct Link:
  • 8
    Prakken B, Kuis W, van Eden W, Albani S. Heat shock proteins in juvenile idiopathic arthritis: keys for understanding remitting arthritis and candidate antigens for immune therapy. Curr Rheumatol Rep 2002; 4: 466–73.
  • 9
    Nishikawa H, Kato T, Tawara I, Saito K, Ikeda H, Kuribayashi K, et al. Definition of target antigens for naturally occurring CD4 CD25 regulatory T cells. J Exp Med 2005; 201: 681–6.
  • 10
    Kamphuis S, Kuis W, de Jager W, Teklenburg G, Massa M, Gordon G, et al. Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 2005; 366: 50–6.
  • 11
    Lee L, Buckley C, Blades MC, Panayi G, George AJ, Pitzalis C. Identification of synovium-specific homing peptides by in vivo phage display selection. Arthritis Rheum 2002; 46: 2109–20.
    Direct Link:
  • 12
    Prakken BJ, Samodal R, Le TD, Giannoni F, Yung GP, Scavulli J, et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A 2004; 101: 4228–33.
  • 13
    Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev 2001; 182: 68–79.
    Direct Link:
  • 14
    O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004; 10: 801–5.
  • 15
    Von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005; 6: 338–44.
  • 16
    Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol 2005; 6: 353–60.
  • 17
    Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptide. Immunity 1994; 1: 751–61.
  • 18
    Schett G, Tohidast-Akrad M, Steiner G, Smolen J. The stressed synovium. Arthritis Res 2001; 3: 80–6.
  • 19
    Gattorno M, Prigione I, Vignola S, Falcini F, Chiesa S, Moranti F, et al. Levels of soluble CD27 in sera and synovial fluid and its expression on memory T cells in patients with juvenile idiopathic arthritides. Clin Exp Rheumatol 2002; 20: 863–6.
  • 20
    Murray KJ, Grom AA, Thompson SD, Lieuwen D, Passo MH, Glass DN. Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol 1998; 25: 1388–98.
  • 21
    Coutinho A, Hori S, Carvalho T, Caramalho I, Demengeot J. Regulatory T cells: the physiology of autoreactivity in dominant tolerance and quality control of immune responses. Immunol Rev 2001; 182: 89–98.
    Direct Link:
  • 22
    Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD4+CD25+ regulatory cells that control intestinal inflammation. J Exp Med 2000; 192: 295–302.
  • 23
    Maloy KJ, Salaun L, Cahill R, Dougan G, Saunders NJ, Powrie F. CD4+CD25+ T cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 2003; 197: 111–9.
  • 24
    Murphy TJ, Choileain NN, Zang Y, Mannick JA, Lederer JA. CD4+CD25+ regulatory T cells control innate immune reactivity after injury. J Immunol 2005; 174: 2957–63.
  • 25
    Prakken BJ, Roord S, van Kooten PJ, Wagenaar JP, van Eden W, Albani S, et al. Inhibition of adjuvant-induced arthritis by interleukin-10–driven regulatory cells induced via nasal administration of a peptide analog of an arthritis-related heat-shock protein 60 T cell epitope. Arthritis Rheum 2002; 46: 1937–46.
    Direct Link:
  • 26
    Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25: 1991–4.
  • 27
    Ravelli A, Magni-Manzoni S, Viola S, Pistorio A, Ruperto N, Martini A. Factors affecting the efficacy of intraarticular corticosteroid injection of knees in juvenile idiopathic arthritis. J Rheumatol 2001; 28: 2100–2.
  • 28
    Luross JA, Heaton T, Hirst TR, Day MJ, Williams NA. Escherichia coli heat-labile enterotoxin B subunit prevents autoimmune arthritis through induction of regulatory CD4+ T cells. Arthritis Rheum 2002; 46: 1671–82.
    Direct Link:
  • 29
    De Kleer IM, Wedderburn LR, Taams LS, Patel A, Varsani H, Klein M, et al. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 2004; 172: 6435–43.
  • 30
    Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000; 164: 183–90.
  • 31
    Fisson S, Djelti F, Trenado A, Billiard F, Liblau R, Klatzmann D, et al. Therapeutic potential of self-antigen-specific CD4+CD25+ regulatory T cells selected in vitro from a polyclonal repertoire. Eur J Immunol 2006; 36: 817–27.
    Direct Link:
View Full Article (HTML) Get PDF (217K)